Zurück
Werbung
Thema sollten wir nicht weiter breittreten..
--
Was anderes: Interessantes zu M032 (und im Nachgang auch zu G207)
"..Among OVs, oHSV is the furthest along in the clinic. OncoVEXGMCSF or currently named Talimogene laherparepvec (T-Vec) has completed a pivotal phase III trial, OPTiM, in recurrent melanoma, where it demonstrated a significant improvement in the durable response rate and a longer median survival (43). Its New Drug Application (NDA) received a highly favorable review by the FDA advisory review committee and is awaiting final FDA notice. Four oHSVs (1716, G207, G47Δ, and M032) are or have been in clinical trials for patients with recurrent malignant gliomas (Table 1) (31). The neurovirulence gene γ34.5 is deleted in all of them. In addition, both G207 and G47Δ have mutations in the ICP6 gene making viral infection more specific to dividing cancer cells (30). Deletion of the γ34.5 gene in these oHSVs (1716, G207, and M032) limits or even abolishes their replication in GSCs (44, 45). Unfortunately, this was not determined until after clinical trials with 1716 and G207 were initiated and demonstrates the value of GSC models. Deletion of the ICP47 gene in G207, to create G47Δ, restores replication in GSCs (44), without compromising safety (46). The γ34.5-deleted oHSV M032 expresses both human p40 and p35 IL-12 subunits (47)..."
Artikel sieht älter aus, ist aber erst seit 5.2.16 online
www.ncbi.nlm.nih.gov/pmc/articles/PMC4743035/
clinicaltrials.gov/ct2/show/NCT02062827?term=M032&rank=1
--
Was anderes: Interessantes zu M032 (und im Nachgang auch zu G207)
"..Among OVs, oHSV is the furthest along in the clinic. OncoVEXGMCSF or currently named Talimogene laherparepvec (T-Vec) has completed a pivotal phase III trial, OPTiM, in recurrent melanoma, where it demonstrated a significant improvement in the durable response rate and a longer median survival (43). Its New Drug Application (NDA) received a highly favorable review by the FDA advisory review committee and is awaiting final FDA notice. Four oHSVs (1716, G207, G47Δ, and M032) are or have been in clinical trials for patients with recurrent malignant gliomas (Table 1) (31). The neurovirulence gene γ34.5 is deleted in all of them. In addition, both G207 and G47Δ have mutations in the ICP6 gene making viral infection more specific to dividing cancer cells (30). Deletion of the γ34.5 gene in these oHSVs (1716, G207, and M032) limits or even abolishes their replication in GSCs (44, 45). Unfortunately, this was not determined until after clinical trials with 1716 and G207 were initiated and demonstrates the value of GSC models. Deletion of the ICP47 gene in G207, to create G47Δ, restores replication in GSCs (44), without compromising safety (46). The γ34.5-deleted oHSV M032 expresses both human p40 and p35 IL-12 subunits (47)..."
Artikel sieht älter aus, ist aber erst seit 5.2.16 online
www.ncbi.nlm.nih.gov/pmc/articles/PMC4743035/
clinicaltrials.gov/ct2/show/NCT02062827?term=M032&rank=1
